Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Lithuania

Marie Skłodowska-Curie Action · Running

psilonova psiloNOVA: the new bridges by psilocybin to treat depression, from gut to brain

Coordinator
Vilniaus Universitetas, Lithuania
Runs
1 April 2027 to 31 March 2029
Status
Running
EU funding
€181k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101277996

What the project is doing

In the project's own words, from its summary on CORDIS.

The psiloNOVA project aims (i) to investigate the acute and sustained modulatory effects of psilocybin on gut-brain and hypothalamic-pituitary-interrenal (HPI) (HPA-like) axes; (ii) to evaluate the promotion of neuroplasticity, neuroprotection, and immune regulation; and (iii) to identify molecular and cellular markers that define antidepressant responses in a depressive-like state zebrafish model. Using transgenic zebrafish, the project will integrate molecular profiling, along with high-resolution imaging approaches to evaluate serotonergic and stress-related signaling, synaptogenesis, neuroprotection and remodeling of the myenteric plexus, as well as immunomodulation and microglial/enteric muscularis macrophage dynamics after a single dose. psiloNOVA is highly relevant to the MSCA Work Programme by addressing an urgent societal challenge, such as Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD), through cutting-edge and interdisciplinary research that will advance European excellence and reference in neuroscience and psychopharmacology.

The interdisciplinary methods designed and chosen to answer our objectives will provide the first multilevel mechanistic evidence of psilocybin’s sustained antidepressant effects, bridging central and enteric nervous system regulation. The results will expand studies on psychedelic compounds with potential therapeutic applications, promoting more effective and well-tolerated responses. Additionally, the outcomes will better define the precise markers associated with antidepressant responses triggered by psilocybin.

Topics

Who is involved

OrganisationCityCountryRole
Vilniaus UniversitetasVilniusLithuaniaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI